853426-35-4
853426-35-4
Chemical Structure
Blinatumomab
Synonym(s): bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO
- CAS No.: 853426-35-4
- Formula:N/A
- Molecular Weight:(54.09 kDa)
SMILES: [Blinatumomab]
Biological Activity: Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Blinatumomab | 97.33% | Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kantarjian H, et, al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. [Content Brief]
- [2]. Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003 Apr 15;170(8):4397-402. [Content Brief]
- [3]. Hoffman LM, et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014 Mar 31;4:63. [Content Brief]
- [4]. Zhang R, et al. The establishment and application of CD3E humanized mice in immunotherapy[J]. Experimental Animals, 2022, 71(4): 442-450. [Content Brief]
Keywords
